Please assess the completion status of the following clinical trial:

Trial Title: Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Subject and Control Inclusion Criteria~1. Participants have a Body Mass Index (BMI) between 20-25 or 35 and above.~2. Adults aged 18-65~Exclusion Criteria:~1. Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory conditions or diabetes mellitus~2. Antibiotic use within the past 4 weeks (they can be enrolled after a four week washout period and subsequent use during the 6 month study duration does not exclude them)~3. Bowel preparation for colonoscopy within the past week~4. Significant bowel surgery other than hysterectomy or appendectomy~5. Pregnancy or plans to become pregnant within the study time frame~6. Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.~7. Age\<18 or vulnerable adults -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Flexible Sigmoidoscopy (Type: OTHER): Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota

Based on this trial design, predict the completion outcome and termination type (if applicable).